PL EN


Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
Tytuł artykułu

Syntheses and In Vitro Antitumor Activity of 3-Amino-N-(4-chlorobenzenesulfonyl)guanidine Derivatives Containing N'-Arylidene Moiety

Identyfikatory
Warianty tytułu
Języki publikacji
EN
Abstrakty
EN
The syntheses of new 3-arylideneamino-1-(2-alkythio-4-chloro-5-methylbenzenesulfonyl) guanidines 2-8 and 1-arylidene-2-(2-alkylthio-4-chloro-5-R3-benzenesulfonyl)- 3-methylaminoguanidines 9-16 are described. The in vitro antitumor screening of compounds 2, 3, 9 and 10 was evaluated at the Institute of Pharmacy, University of Greifswald. The remaining compounds 5, 11-14 and 16 were screened at the National Cancer Institute (NCI) for their activities against a panel of 55 human tumor cell lines, and relationships between structure and anticancer activity in vitro are discussed. The highest anticancer activity was found for 2-(2-benzylthio-4-chloro-5-methylbenzenesulfonyl)- 3-methylamino-1-(5-nitrothienylidene)guanidine (12) (GI50 in the range 0.3-0.6 _M), while other compounds exhibit reasonable (16) or moderate ( 9, 13) anticancer activities.
Rocznik
Strony
369--379
Opis fizyczny
Bibliogr. 20 poz., rys.
Twórcy
  • Department of Chemical Technology of Drugs, Medical University of Gdańsk, Al. Gen. J. Hallera 107, 80-416 Gdańsk, Poland
autor
  • Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, University of Greifswald, L.-John Str. 17, D-17487 Greifswald, Germany
autor
  • Department of Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy, University of Greifswald, L.-John Str. 17, D-17487 Greifswald, Germany
Bibliografia
  • 1. Casini A., Scozzafava A., Mastrolorenzo A. and Supuran C.T., Curr Cancer Drug Targets, 2,55 (2002).
  • 2. Scozzafava A., Owa T., Mastrolorenzo A. and Supuran C.T., Curr. Med. Chem., 10, 925 (2003).
  • 3. Scozzafava A., Casini A. and Supuran C.T., Curr. Med. Chem., 9, 1167 (2002).
  • 4. Supuran C.T., Casini A. and Scozzafava A., Med. Res. Rev., 23, 535 (2003).
  • 5. Artico M„ Il Farmaco, 51, 305 (1996).
  • 6. Leung D., Abbenante G. and Fairlie D., J. Med. Chem., 43, 305 (2000).
  • 7. Vermeire K., Bell T.W., Choi H.J., Jin Q., Samala M.F., Sodoma A., de Clercq E. and Schols D., Mol. Pharmacol., 63, 203 (2003).
  • 8. Chem J., Leu Y., Wang S., Jou R., Lee C., Tsou P., Hsu S., Liaw Y. and Lin H., J. Med. Chem., 40,2276 (1997).
  • 9. Pindur U. and Lemster T., Pharmazie, 53, 79 (1998).
  • 10. Stanek J., Caravatti G., Capraro H-G., Furet P., Mett H., Schneider R and Regenass U., J. Med. Chem., 36, 46(1993).
  • 11. Stanek J., Caravatti G., Frei J., Furet R, Mett H., Schneider R and Regenass U., J. Med. Chem., 36,2168 (1993) .
  • 12. Matsumo S., Myaguchi M., Ito A., HaraN. and SakuradaN., Jpn. Pat. 06,192,215; C.A., 121, 300598t (1994) .
  • 13. Stawinski J., Bednarski P., Grunert R. and Reszka P., Polish J. Chem., 77, 53 (2003).
  • 14. Brzozowski Z. and S^czcwski F., Eur. J. Med. Chem., 37,285 (2002).
  • 15. Bernhardt G., Reile H., Bimbock H., SpruB T. and Schonenberger H., J. Cancer Res. Clin. Oncol., 118, 35 (1992).
  • 16. Details of this system and the information which is encoded by the activity pattern over all cell lines have been also described in our previous paper ref. [13].
  • 17. Boyd M.R., Am. Assoc. Cancer Res., 30, 652 (1989).
  • 18. Monks A.P., Scudiero D.A., Skehan P., Shoemaker K.D., Poull D., Vistica C., Hose C., Langley J., Cronise P., Vaigro-Wolff A., Gray-Goodrich M., Cambell H., Mayo M. and Boyd M., J. Natl. Cancer Inst., 83, 757(1991).
  • 19. Weinstein J.N., Myers T.G., O'Connor P.M., Friend S.H., Fomance A.J., Jr., Kohn K.W., Fojo T., Bates S.E., Rubinstein L.V., Anderson N.L., Buolamwini J.K., van Osdol W.W., Monks A.P., Scudiero D.A., Sausiville E.A., Zaharevitz D.W., Bunow B., Viswanadhan V.N., Johnson G.S., Wittes R.E. and Pauli K.D., Science, 275, 343 (1997).
  • 20. Stawinski I., Polish! Chem., 75, 1309 (2001).
Typ dokumentu
Bibliografia
Identyfikator YADDA
bwmeta1.element.baztech-article-BUJ1-0023-0182
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.